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SUMMARY
Tolerance development after successful long-term treatment of bipolar disorder is under
recognized, as are ways to prevent or show its occurrence or reverse it once it has occurred.
We review the clinical literature which suggests that tolerance can develop to most treat-
ment approaches in bipolar illness and present an animal model of tolerance development
to anticonvulsant effects of carbamazepine or lamotrigine on amgydala-kindled seizures. In
this model tolerance does not have a pharmacokinetic basis, but is contingent upon the
drug being present in the brain at the time of amygdala stimulation. The occurrence of
seizures in the absence of drug is sufﬁcient to reverse tolerance and re-establish anticonvul-
sant efﬁcacy. Based on the model, we hypothesize that some episode-induced compensatory
adaptive changes in gene expression fail to occur in tolerant subjects and that episodes off
medication re-induce these changes and renew drug effectiveness. Approaches that slow
or reverse tolerance development in the animal model are reviewed so that they can be
tested for their applicability in the clinic. Criteria for assessing tolerance development are
offered in the hope that this will facilitate a more systemic literature about its prevalence,
prevention, and reversal. Careful longitudinal monitoring of episode occurrence is essential
to understanding tolerance development in the affective disorder and its treatment.
Introduction
Tolerance to the antinociceptive effects of carbamazepine (CBZ) in
the long-term treatment of trigeminal neuralgia and related parox-
ysmal pain syndromes has been widely recognized as a substantial
problem after initial evidence of acute efﬁcacy in about 80% of pa-
tients [1–4]. Less well known is the potential for tolerance devel-
opment during long-term treatment with CBZ and other anticon-
vulsants in seizure disorders and in patients with bipolar disorder.
However, close examination of the course of illness in initial
good responders to CBZ in mono- or poly-therapy reveals that
after years of sustained remission, episodes of mania and/or de-
pression can begin to break through prophylaxis with increasing
frequency, intensity, or duration in a pattern that is highly sug-
gestive of the development of tolerance [5–8]. Similar tolerance
patterns (i.e., loss of effectiveness of a treatment after a period
of good initial responsivity) have also been reported for lithium
(Li)[7,9], valproate (VPA), and lamotrigine (LTG) in bipolar dis-
order [8] as well as with antidepressant treatment in the prophy-
laxis of recurrent unipolar depression [10,11], Given this poten-
tial for loss of responsiveness after an initial period of sustained
response to many drugs used in the long-term treatment of bipo-
lar disorder patients, a closer examination of the phenomenon,
potential mechanism, and therapeutic approaches appears
indicated.
Differentiating the Development of Tolerance
from Other Reasons for Loss of Effectiveness
A. Nonresponse from the Outset
For tolerance to be inferred there must be clear evidence of an
initial successful treatment response and not just a spontaneous
course of illness variation, such that the patient was not really a
responder. For example, in those with a pattern of pretreatment
rapid cycling bipolar disorder (four or more episodes/year), a pe-
riod of several years without any episodes on a new treatment
begins to be highly suggestive of effective prophylaxis. However,
in someone showing a pattern of more intermittent episodes ev-
ery 1–2 years, a very much longer time of prospective observation
is required in order to reliably demonstrate initial treatment effec-
tiveness and, subsequently, even longer periods of time to evaluate
whether a tolerance pattern emerges.
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B. Another form of Acquired Loss of
Responsiveness– Discontinuation-Related
Refractoriness
If an effective treatment is discontinued and episodes emerge, this
is not evidence of tolerance, but likely reﬂects the reemergence of
the illness in the absence of adequate treatment. Such episodes
emerging off of treatment can also ultimately lead to the phe-
nomenon of discontinuation-related refractoriness. When a good
responder to Li, for example, stops the treatment and episodes re-
occur, upon reestablishing the same Li treatment regimen, a good
clinical response similar to that seen previously may not occur
[7,8,12–14].
Such a phenomenon has also been observed in patients discon-
tinuing long-term previously effective antidepressant prophylaxis
in unipolar illness [8,15]. Several investigators have raised ques-
tions about the occurrence of this phenomenon in bipolar disor-
der [16,17], but their observations that most patients who dis-
continue treatment then reacquire their initial responsivity does
not invalidate the systematic, detailed, and careful observations
in a small percentage of individual patients who fail to rerespond
[7,8,12,13,18,19]. Aside from clear-cut discontinuation-induced
refractoriness, a mixture of this mechanism and apparent toler-
ance development may occur in some covertly noncompliant pa-
tients who repeatedly miss doses, drop their blood levels substan-
tially, and show a progressive pattern of breakthrough episodes.
Clinical Tolerance Development
Tolerance to CBZ
In our initial studies of long-term prophylaxis involving regimens
that utilized CBZ, we saw an initial 50–60% response rate even
in highly treatment-refractory rapidly cycling patients, but then
some 30–40% of these patients began to show a pattern of loss
of efﬁcacy consistent with the development of tolerance [6]. In
the additional follow-up of a total of 44 patients for an average of
6.9 years, 29 individuals (65.9%) were highly responsive to CBZ
in combination with other drugs, and tolerance developed in 13
of these patients, or 44.8%. Episodes began to breakthrough CBZ
treatment after an average of 2.8–0.9 years of pharmacoprophy-
laxis. One such patient is illustrated in Figure 1.
Tolerance to VPA
In another group of patients initially treated with regimens involv-
ing VPA, we saw a lesser degree of tolerance development, that is,
about 25% of the initially responsive patients lost their good effect
after an average of 2–4 years (see example in Figure 2) [8].
Tolerance to Li
Patients admitted to our tertiary-referral clinical research unit at
the National Institute of Mental Health (NIMH) almost always
had a history of nonresponsiveness to Li and sought alternative
protocols and treatment studies. When we systematically charted
these patients’ previous course of illness and medication response,
a tolerance pattern had occurred in 34.3% of patients, while the
phenomenon of discontinuation-related refractories was seen in
another 13.6% [12]; 43.9% of the patients showed a pattern of
unresponsiveness to acute and/or prophylactic Li from the outset,
while 7.6% were sustained partial responders.
Tolerance to Other Anticonvulsants and
Treatments Used in Long-term Prophylaxis
of Bipolar Disorder
While we did not have a large enough series of patients fol-
lowed prospectively on other anticonvulsants to give reliable per-
centages of tolerance development, in several instances we saw
patients with clear-cut periods of treatment responsiveness who
then began to show a pattern of gradual reemergence of episodes.
An example of such apparent tolerance to gabapentin (GPN) ob-
served prospectively with daily ratings on the NIMH-Life Chart
MethodTM (NIMH-LCM) [8] is illustrated in Figure 3, although
the literature remains mixed as to the overall effectiveness of this
agent in monotherapy or combination therapy [20].
In several instances when patients’ prospective course of illness
was rated on a daily basis, tolerance to LTG was observed. In this
case the literature is highly supportive of the efﬁcacy of LTG in the
prevention of episodes of bipolar disorder, and it is FDA approved
f o rt h i si n d i c a t i o n .
In long-term treatment of 27 patients with the high-potency
benzodiazepine clonazepam, Kishimoto el al. [21] reported an ini-
tial response rate of 84%, but then observed a very high rate of
loss of efﬁcacy via tolerance. In patients with refractory epilepsy
with a good initial response to the high-potency benzodiazepine
clobazam, a loss of efﬁcacy occurs rapidly in a large proportion of
patients limiting the utility of this treatment [22].
In a prospective follow-up of 525 patients during naturalistic
treatment, 195 (37.1%) were clear-cut responders for a minimum
of 6 months. Of these 16.4% showed a tolerance pattern to treat-
ment with an average of three drugs in combination after a mean
of 14.8 ± 7.5 months of response [23]. Thus tolerance can occur
not only to individual medications, but also to their use in complex
combinations.
Preclinical Tolerance Studies:
Implications for Clinical Tolerance
Contingent Tolerance to the Anticonvulsant
Effects of CBZ and LTG on Amygdala-Kindled
Seizures
Animals given once-daily amygdala-kindled stimulations above
their after discharge (AD) threshold will eventually develop re-
liable seizures [24,25]. CBZ and LTG are highly effective in pre-
venting these fully developed amygdala-kindled seizures when the
drugs are administered between 15 min and 1 h prior to amyg-
dala stimulation. However, after repeated daily pretreatments with
these drugs (Figure 4), animals increasingly begin to show break-
through seizures and eventually completely lose their anticonvul-
sant response to CBZ or LTG [26–32].
This is a pharmacodynamic effect because animals that are re-
peatedly treated with the same dose of drug immediately after
a kindled seizure has occurred on a daily basis do not develop
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Figure 1 Phases in illness evolution and treatment response in a bipolar
female. This patient’s course of illness progressed from a pattern charac-
terized by isolated, intermittent episodes (not illustrated) to a continuous,
rhythmic phase with ultrarapid and ultradian cycling in 1985. Manic sever-
ity is rated above the line and depression severity below; years are on the
abscissa. After 3 years well on carbamazepine (plus lithium which had pre-
viously been ineffective in monotherapy), she began to show a tolerance
pattern of intermittent mild, then moderate, then severe breakthrough de-
pressionsin1989and1990.Shedidnotrespondtovalproate(eitherbecause
of cross-tolerance to carbamazepine or an entire lack of responsivity to it).
Shedidwellforaperiodwiththeadditionofdesipramine,butmadeasevere
suicide attempt in 1994, and then appeared to have a renewed response to
carbamazepine.
tolerance when the drug is switched to a prestimulation time
frame. Thus, the development of tolerance is contingent upon the
drug being present in the brain at the time of electrical stimulation
of the amygdala. Similar tolerance has been observed with other
drugs, including benzodiazepines and alcohol [33–36].
This contingent tolerance phenomenon has the property that it
can be overcome or reversed if the animal is given several days
of amygdala-kindled seizures in the absence of drug [26]. Even
more remarkably, if animals that have become tolerant to the an-
ticonvulsant effects of CBZ or LTG continue to receive the drug
on a once-daily basis, but immediately after the kindling stimula-
tion and the occurrence of a seizure, this too is associated with the
renewal of anticonvulsant efﬁcacy. This tolerance reversal despite
continued daily drug administration further demonstrates the con-
tingent and pharmacodynamic mechanisms involved in this type
of tolerance.
A related phenomenon of contingent inefﬁcacy has also been
demonstrated for both CBZ and LTG. These drugs are not effec-
tive in preventing the initial, developmental phase of kindling
which occurs from the onset of stimulations to the ﬁrst full blow
amygdala-kindled seizure [26,31,37] However, if either drug is
given prior to (but not after) each amygdala stimulation in this
initial developmental phase of kindling, the drugs will no longer
be effective in treating the full-blown kindled seizures once they
emerge. In this case using a drug when it is otherwise ineffective
may have adverse consequences for later responsiveness when it
would ordinarily be effective.
Potential Mechanisms of Contingent Tolerance
Development and its Reversal with Seizures
in the Medication-Free State
In an effort to examine the molecular mechanisms involved in
tolerance development, we treated one group of animals with
once-daily CBZ until tolerance had developed and full-blown
seizures had reemerged, and a second group with CBZ given only
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Figure 2 This lithium-nonresponsive patient (1979–1981) showed an ex-
cellent response to the addition of valproate (1983–1986), but manias of
increasing frequency and moderate severity and mild to moderately se-
vere depressions began to break through treatment (especially in 1987 and
1988)despiteattemptsatadjunctivetreatmentwithantipsychotics,antide-
pressants, and benzodiazepines. A severe mania ensued off valproate in
1989despitecontinuedtreatmentwithlithium,butafterseveralmonthsoff
valproate, the drug was reintroduced, and the patient appeared to regain
responsiveness to it (1990–1995).
after seizures had occurred so that they were not tolerant (even
though they had had the same number of stimulations and drug
administrations) [26]. Another group of animals were given kin-
dled seizures without any medications, and a fourth group was
implanted but received only sham stimulation. We found that
amygdala-kindled seizures in the absence of drug and in the ani-
mals given CBZ after their seizures had occurred (such that they
were not tolerant), both manifested robust seizure-induced in-
creases in the mRNA for thyrotropin-releasing hormone (TRH)
which has putative anticonvulsant properties [38]. In contrast, in
the CBZ tolerant animals, their full-blown seizures were not asso-
ciated with an increase in TRH mRNA in the dentate gyrus of the
hippocampus.
A similar failure of seizure-induced adaptations to occur selec-
tively in animals that become tolerant to the anticonvulsant effects
of CBZ was observed in studies of the GABA-A receptor and its
alpha-4 subunit [26,39]. This was a highly selective occurrence as
other subunits (beta 1 and 3) continued to be induced after kin-
dled seizures in the CBZ -tolerant animals.
We surmised that it was these seizure-induced endogenous an-
ticonvulsant adaptations (such as increases in TRH and GABA-A
receptor subunits) that were usually enabling the anticonvulsant
effects of CBZ, and that when these adaptations failed to occur de-
spite an induced seizure, CBZ was no longer effective, that is, tol-
erance is manifest [37]. Consistent with this interpretation, when
TRH was administered bilaterally into the hippocampus of animals
who were tolerant to CBZ, anticonvulsant effectiveness was re-
stored [40].
Table 1 lists the series of biochemical entities that we explored
in animals which were CBZ -tolerant animals compared to those
medication-free or nontolerant (when CBZ was given immediately
after the seizures). Since many of the mRNA and receptor changes
that fail to occur following seizures in CBZ -tolerant animals are
for substances with known anticonvulsant effects, their combined
failure could contribute to the manifestation of tolerance [26,37].
At the same time, these observations could explain why sev-
eral seizures induced in the absence of CBZ or LTG are sufﬁ-
cient to reverse the tolerance process. These seizures would, again,
induce TRH, the alpha-4 subunit of the GABA-A receptor and
the other endogenous anticonvulsant substances listed in Table 1
which would restore anticonvulsant effectiveness. That is, we pos-
tulate that CBZ and LTG require the presence of a certain amount
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Figure 3 In June 1997, gabapentin augmentation resulted in sustained antimanic effects, but after a period of 6 months without depressions, depressive
episodesofincreasingdurationagainbegantomanifestin1997and1998astheyhadpriortogabapentinin1996and1997.Notewhiledepressionsreturned,
manias did not, suggesting differential vulnerability to tolerance development between the two mood poles.
of endogenous anticonvulsant modulators in order to be effective
against amygdala-kindled seizures.
Consistent with this viewpoint are the observations of a “time-
off from last seizure” effect [26]. The increase in TRH mRNA leads
to increases in TRH protein that remain for some 3–5 days after
a seizure [41]. If the increases in TRH and related substances are
important to the anticonvulsant effects of CBZ and LTG, the drugs
should work well in the ﬁrst several days after the last seizure has
occurred, but should fail to exert anticonvulsant effects if animals
are given a time-off vacation from kindled seizures for a period
of at least 5 days. By this time the transient seizure-induced in-
creases in TRH protein would have dissipated, and, accordingly,
these drugs would lose their anticonvulsant effectiveness.
Ratio of Pathological to Adaptive Factors
as a Determinant of Cyclicity
Given these observations, one is in a position to postu-
late some of the mechanisms involved in the cyclic reemer-
gence of seizures leading to full-blown loss of efﬁcacy [42–45].
The initial application of CBZ prior to a kindled seizure would re-
sult in an anticonvulsant effect on each of the ﬁrst several days
of treatment (Figures 4 and 5). However, seizures might begin to
break through this effective prophylaxis based on three phenom-
ena. One is the addition of further kindled stimulations that would
hypothetically increase illness drive (increase the pathological kin-
dled memory trace). The second is the failure of these seizures in
treated animals to induce the usual range of endogenous adapta-
tions that would normally occur as listed in Table 1. The third is
that with the passage of time, whatever seizure-induced endoge-
nous adaptations had occurred would now begin to dissipate.
As illustrated in Figure 5, this would render the combined ef-
fects of the exogenous medication and endogenous anticonvulsant
actions inadequate to continue to convey anticonvulsant efﬁcacy.
However, with the recurrence of several breakthrough seizures
even in partially tolerant animals, some of the endogenous an-
ticonvulsant substances might be sufﬁciently induced in order to
renew efﬁcacy for a short period of time, but then as the endoge-
nous adaptations begin to dissipate, seizures would again break
through, and this process would be reiterated until complete tol-
erance occurred [43,44].
Based on this analysis, we have suggested that parallel princi-
ples and processes could occur in bipolar disorder (in very differ-
ent time frames and in different neuroanatomical and neurotrans-
mitter systems) following effective treatment when episodes begin
to reemerge with increasing frequency, severity, or duration as
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Figure 4 Variable and oscillating patterns of tolerance emergence to car-
bamazepine’s anticonvulsanteffects is illustrated in two individual rats. Kin-
dling stimulation was administered daily for 1 second at 400 μAa n dw a s
preceded by carbamazepine (15 mg/kg i.p.). Motor seizure duration is plot-
ted on the ordinate and days of electrical stimulation (with drug treatment)
are plotted on the abscissa. Breakthrough seizures appeared rapidly in an
episodic fashion (top) or only partially after a long delay (bottom) in these
two individual animals.
tolerance develops. We posit it is the ratio of endogenous patho-
logical alterations (the “bad guys”) to endogenous adaptive alter-
ation (the “good guys”) combined with the exogenous effects of
drugs that determines whether or not affective episodes are sup-
pressed, occur episodically, or occur regularly as complete toler-
ance develops [43,44].
An important clinical and theoretical implication of the pos-
tulate would be that any neurobiological abnormality observed
in the affective disorders would need to be differentiated into at
least two categories, each with differential therapeutic implica-
tions [42,45]. Abnormalities representing the primary pathologi-
cal processes driving illness progression (i.e., the “bad guys”), such
as increases in corticotropin-releasing hormone (CRH), should be
targeted for amelioration or prevention. In contrast, those repre-
senting secondary adaptive ones (i.e., the putative “good guys”),
such as increases in TRH, should be further enhanced by therapeu-
tic interventions. Another obvious implication of these principles
is that the illness and its neurobiology is constantly in ﬂux, such
that any cross-sectional neurobiological assessment can only pro-
vide a snapshot of what is likely a highly variable and ultimately a
potentially progressive process [45,46].
In the case of tolerance development to drugs on amygdala-
kindled seizures, some animals lose anticonvulsant efﬁcacy very
rapidly and completely, while others sustain responsivity to a drug
for substantial periods of time before losing it in a slow intermit-
tent or cyclic fashion (see Figure 4). A similar wide individual
variability is seen in clinical tolerance development in the affec-
tive disorders. In both of these instances, one would postulate that
the individual differences in rate of tolerance development might
relate to both an individual’s baseline and episode-related ratio of
pathological to adaptive factors [44,45].
In this analysis we have highlighted the changing ratio of patho-
logical versus adaptive alterations that occur at the level of changes
in gene transcription. A new level of modulation of these changes
has recently been documented in epigenetic alterations, based on
environment- and drug-induced changes in DNA methylation and
histone acetylation and methylation [46–50]. Such changes which
affect the ease of gene transcription could account for the induc-
tion or suppression of a whole array of neurobiological alterations
such as those illustrated in Table 1.
Potential Clinical Approaches to Slowing
Tolerance Development: Implications from
Preclinical Models
Decreasing the forces that propel the pathological processes in-
volved in the kindled memory trace is one way to slow tolerance
development. This involves stimulating animals with less intense
current or less frequently [26,37]. However, while these ways of
lowering illness drive are available in the experimental situation,
in clinical approaches to patients with recurrent mood disorders,
lowering illness drive is obviously more problematic. However, it
could include decreasing the impact of stressful life events and
decreasing substance use, as well as intervening early to prevent
episode accumulation [50]. Clearly, most of the clinical attempts
at slowing tolerance development based on the rodent kindling
model would rely on alterations in the medication strategy, as
listed in Table 2A. If anticonvulsant treatment is started early in
the course illness development after only one or two full-blown
kindled seizures have occurred, this results in less rapid develop-
ment of tolerance compared with animals that have had scores of
amygdala-kindled stimulations [26].
We can ask whether this and the other principles observed in
the preclinical kindling model are applicable to tolerance devel-
opment in the affective disorders. In our clinical data on CBZ tol-
erance cited, the 13 patients who did develop tolerance had an
average of 5 hospitalizations for mania compared to only 2.8 in
those who remained responsive. Thus, clinically, illness drive as
reﬂected in the number of prior episodes may relate to the like-
lihood of tolerance development. Also there are a wealth of data
indicating that Li is less effective in those with more prior com-
pared to fewer prior episodes [8], and whether some of this poorer
long-term responsivity relates to ultimate tolerance development
remains to be clariﬁed.
We have also seen that using stable higher doses of CBZ, that
is, well above the animal’s seizure threshold, results in less rapid
tolerance development compared with minimally effective doses.
This principle would have very obvious clinical implications in
the treatment of affective disorders wherein clinicians routinely
attempt to treat patients with the lowest effective dose of drug.
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Table1 Selectivefailureofsomekindledseizure-inducedneurochemicalchangesduringcontingenttolerancetotheanticonvulsanteffectsofcarbamazepine
(CBZ)
In nontolerant animals,a In tolerant animals, some ∗ = Putative endogenous
seizure-induced alterations include: seizure-induced alterations either: anticonvulsant effect is lost
Continue to occur Fail to occur
↑ c-fos mRNA ↑ c-fos
↑ Diazepam receptors ↑ Diazepam-R
↑ GABA-A receptors ↑ GABA A-R ∗
[3–1-1] musimol
↑∝ 4 subunit ↑ μ4 subunit ∗
↑ Beta 1 & 3 subunits ↑ beta 1 & 3 subunits
↑ TBPS binding ↑ TBPS ∗
↑ Glucocorticoid RmRNA ↑ Glucocorticoid R ∗
↑ Mineralocorticoid RmRNA ↑ Mineralocorticoid R
↑ BDNF mRNA ↑ BDNF
↓ NT3 mRNA ↓ NT3
↑ TRH mRNA ↑ TRH ∗
↑ CRH mRNA ↑ CRH
↑ CRH-BP mRNA ↑ CRH-BP
↑ NPY mRNA (↑ NPY) ∗
↑ Enkephalin mRNA (↑ Enkephalin)
↓ Dynorphin mRNA ↓ Dynorphin
CBZ, carbamazepine; DZP, diazepam; GABA, γ-aminobutyric acid; TBPS, [35S]t-butylbicyclophosphorothionate; BDNF, brain-derived neurotrophic factor;
NT3, neurotrophin-3; TRH, thyrotropin-releasing hormone; CRH, corticotropin-releasing hormone; CRH-BP, corticotropin-releasing hormone binding protein;
NPY, neuropeptide Y; (), partial loss; R, receptor.
Data based on studies summarized in Weiss et al., 1995.
aTreated with no drug or with CBZ after each daily amygdala-kindling stimulation; these nontolerant animals were matched for amount of drug and number
of seizures seen in tolerant animals (columns 2 and 3).
This strategy may turn out to be counterproductive in some in-
stances, and use of higher doses that are still well tolerated may
be a more conservative strategy for preventing tolerance develop-
ment to most treatment agents. However, in the case of LTG, use of
high doses paradoxically appears to hasten tolerance development
and various characteristics of LTG and CBZ tolerance development
are quite different despite the fact that they show similar contin-
gent inefﬁcacy and bidirectional cross tolerance [27,28,30,31,44]
(see Table 3).
In addition, if one uses only marginally effective doses of CBZ
or VPA, tolerance to their anticonvulsant effects on amygdala-
kindled seizures occurs more rapidly. However, administration of
minimally effective dose of these two drugs in combination results
in a much slower development of tolerance than to either drug
alone [26]. Thus, it would appear that combinations of drugs, par-
ticularly those with different mechanisms of action may be of some
utility in slowing tolerance development [51]. Each of these sug-
gestions from the preclinical ﬁndings requires further exploration
in the clinic.
Management of Tolerance Once It Has Occurred
If tolerance has already developed, there are several potential ap-
proaches to attempting to reacquire therapeutic efﬁcacy. Again,
none of these seen in the preclinical model has been systematically
tested in the clinical arena, although in some cases there are case
vignettes and small series [8,52] suggesting the utility of a given
approach, but each needs to be more systematically explored. In
the face of tolerance development, it would make the most sense
to switch to other drugs with different mechanisms of action, par-
ticularly ones that do not demonstrate cross-tolerance in animal
models.
Table 4 lists drugs that have been demonstrated to show cross-
tolerance in the amygdala-kindling model, while others do not
show cross-tolerance and their use is associated with renewed an-
ticonvulsant efﬁcacy [28,30,32,44,51,53,54]. For example, there is
clear-cut cross-tolerance between animals that have lost efﬁcacy to
the anticonvulsant effects of CBZ and then are administered LTG
and vice-versa.
Surprisingly, animals that have become tolerant to the anticon-
vulsant effects of CBZ also show cross-tolerance to VPA [54]. Even
though the mechanism of action of these two drugs is quite dif-
ferent, one could imagine that the reduction in GABA-A receptor
number and the amount of its alpha-4 subunit induced by seizures
in CBZ -tolerant animals could contribute to the loss of effective-
ness of VPA, which is thought to act in part by increasing brain
GABA levels (and may require adequate GABA-A receptors), but
the precise mechanisms for this cross-tolerance remain to be seen.
We have seen a bipolar patient who became tolerant to CBZ show
apparent cross-tolerance to VPA (Figure 1) [8].
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Figure 5 Full-blown seizures while medication-free generated endogenous anticonvulsant adaptation (ﬁrst triangle). Anticonvulsant medications produce
a good effect for about 1 week, then seizures start to break through as adaptations wear off. Full-blown seizures occurring during medication tolerance
generate fewer endogenous anticonvulsant adaptations (smaller triangles) and ﬁnally full loss of effect occurs.
One of the ﬁrst clinical reﬂexes in the face of tolerance devel-
opment is to increase the dose of drug and, in some instances, this
may be helpful. However, in the preclinical model, such gradual
dose escalation of CBZ (or the benzodiazepines) usually results in
the relatively rapid development of tolerance, and for this reason
and especially in the face of dose-limiting side effects other strate-
gies may be needed. One highly experimental approach in the face
of inefﬁcacy to a drug that has previously been effective (i.e., cases
of clear-cut tolerance) is to discontinue the use of that drug and
have some of the seizure or affective episodes continue to occur off
that medication in the hope that this would reengender episode-
driven adaptations, and thus renew efﬁcacy once the drug is again
administered.
We have seen several patients with CBZ tolerance rerespond af-
ter a period of time off the drug (Figure 1) [8,52] and another
with tolerance to VPA (and Li) rerespond for a prolonged period
of time after episodes occurred off drug (Figure 2); [8]. In these
cases the episodes in absence of drug would presumably be rein-
ducing positive or therapeutic endogenous adaptations that had
been suppressed during tolerance development as seen in the pre-
clinical model.
Consistent with this therapeutic perspective, Azar et al. [55] ob-
served in a series of 43 patients with epilepsy that brief anticon-
vulsant withdrawal resulted in highly signiﬁcant seizure interval
prolongation once the drugs were restarted. This interval prolon-
gation tended to be greater (25.7 days without a seizure) in those
with a prior history of antiepileptic drug (AED) tolerance than in
those without a tolerance history (14.0 days) [55].
An obvious negative attribute of the attempted drug-free inter-
val as a way of reversing the tolerance process is that it requires
the further experience of additional episodes (seizures or affective
episodes) off drug. However, since the fully tolerant patient has al-
ready developed major breakthrough episodes on drug, the recur-
rence of several more episodes off drug may not be as pernicious as
it might initially appear. However, this liability makes the alterna-
tive approach noted previously of attempting to ﬁnd other drugs
that do not show cross-tolerance a generally preferable clinical and
conceptual strategy. This is further the case, as even the successful
reestablishment of efﬁcacy after a medication-free interval sug-
gests the likelihood that tolerance would again occur in the not
too distant future. This would require yet another off-medication
period for transient efﬁcacy renewal, and this requirement might
repeatedly occur (Figure 6).
In the face of clinical tolerance to the mood-stabilizing anticon-
vulsants such as CBZ, VPA, or LTG in the affective disorders, one
might also consider the utility of using nonanticonvulsant drugs,
such as Li or atypical antipsychotics. These agents have very dif-
ferent mechanisms of action and, in some cases, they may be
sufﬁcient to renew efﬁcacy in the tolerant patient, even without
having to withdraw the drug to which the patient has become
tolerant. Once the mechanisms of the pharmacodynamic (contin-
gent) tolerance process have been further clariﬁed, it may also be
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Table 2
A. Testable clinical predictions about therapeutic approaches to slowing or preventing tolerance development based on the preclinical model
Preclinical study ﬁndings in Rx of daily amygdala-kindled seizures in rodents
Future studies could assess whether there are parallel ﬁndings for clinical
tolerance in epilepsy (likely) or affective illness (questionable)
Tolerance to anticonvulsant effects SLOWED by: Would tolerance in humans be SLOWED by:
1. Higher doses (except with LTG) 1. Maximum tolerated doses rather than minimally effective doses
2. Not escalating doses 2. Stable dosing
3. More efﬁcacious drugs (VPA > CBZ > LTG) 3. Valproate compared with carbamazepine or lamotrigine
4. Treatments initiated early rather than late in the course of kindled seizures 4. Early treatment more effective than that after many episodes have
occurred∗∗
5. Combination treatment (CBZ+VPA and LTG+GPN) 5. Combination treatment rather than monotherapy (as seen with VPA+Li;
VPA+LTG)
6. Reducing illness drive (stimulation intensity) 6. Treatment or prevention of episodes, comorbidities, and stressors
7. Alternating high and low doses of lamotrigine
B. Testable clinical predictions about therapeutic approaches to reversing tolerance once it has occurred
Preclinical study ﬁndings in Rx of daily amygdala-kindled seizures in rodents Future studies could assess whether there are parallel ﬁndings for clinical
tolerance in epilepsy (likely) or affective illness (questionable)
Treatment response in tolerant animals RESTORED by: Would treatment response in humans be RESTORED by:
1. Period of drug discontinuation, then reexposure 1. Period of time off CBZ or VPA in tolerant patients, then re-treatment
(supported by clinical vignettes)
2. Agents with different mechanisms of action that do not cause
cross-tolerance (see Table 3)
2. Anticonvulsant cross-tolerances may or may not be predictive of
cross-tolerances in affective illness
VPA, valproic acid; CBZ, carbamazepine; LTG, lamotrigine; GPN, gabapentin; Li, lithium.
∗∗This prediction has been partially validated for lithium, LTG, and naturalistic treatment.
Table 3 Differential effects of carbamazepine (CBZ) and lamotrigine (LTG) on the development of tolerance to their anticonvulsant effects∗
CBZ (15 mg/kg) LTG (15 mg/kg)
Rapid tolerance to anticonvulsant effects (amygdala kindling) +++ +++
Cross tolerance to other drug +++ +++
“Time-off” effect (seizures enhance efﬁcacy) (4–5 days) (4–5 days)
Seizure threshold change with tolerance ↓↓↓ ↑↑ (possible residual drug effect)
High doses Slow tolerancedevelopment Speed tolerance and are proconvulsant
Alternating high and lowdoses ? Slows tolerance
Chronic non-contingent drug dosing Slows tolerance ?
MK801 on tolerance development No effect Slows (NMDA implicated)
Cross tolerance to valproate Yes No
Valproate combination Slows tolerance ?
Gabapentin augmentation (2 hrs pre-treatment) ? Slows tolerance
(Half hr. pretreatment) ? ↓↓ Stage VI seizures
(Tolerance Reversal) ? +++
NMDA, N-methyl-D-aspartate.
+++ = robust effect; ↓↓↓ = robust decrease; ↓↓ = substantial decrease; ↑↑ = substantial increase; ? = not tested.
∗These differences (despite many similarities in tolerance development and cross tolerance) suggest the importance of examining potential therapeutic
interventions in the clinic based on those hypothesized from the speciﬁc drug and preclinical model.
possible to target them more directly, potentially even at the level
of epigenetic manipulations.
Conclusions
While tolerance development has readily been recognized in the
case of CBZ in the treatment of trigeminal neuralgia or clobazam
treatment of refractory seizure disorders, in the recurrent affective
disorders, tolerance phenomena are not as well characterized in
part because of the very long time frame of observation required
for patients with highly intermittent episodes. Thus, precise his-
tory taking and, preferably, the development of a systematic ret-
rospective and prospective mood chart [8], may be one of the best
ways of achieving appropriate pattern recognition that can dis-
criminate initial nonresponsiveness to a treatment regimen from
that which is acquired by a tolerance process (Figures 1–3) or by
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Table 4 Cross-tolerance demonstrated in anticonvulsant effects on once
daily amygdala-kindled seizures (from Post et al. 2005)
Tolerance on: Shows cross-tolerance with: Efﬁcacy remains to:
Carbamazepine (CBZ) PK 11195 Clonazepam
CBZ-10, 11-epoxide Diazepam
Lamotrigine Phenytonin
Valproatea Levetiracetamb
Lamotrigine (LTG) Carbamazepine Valproate
MK 801c
Gabapentinc
Levetiracetam (LEV) Carbamazepineb
Clonazepam (CLZ) Carbamazepined
aPossibly mediated by CBZ tolerance decreasing GABA-A receptors and
itsalpha-4 subunits.
bUnidirectional cross-tolerance LEV to CBZ, but not CBZ to LEV.
cThese drugs slow LTG tolerance development.
dFrom Kim et al. 1992 also suggesting unidirectional cross-tolerance.
the completely different mechanism of discontinuation-induced
refractoriness [12,13].
Some investigators question whether either the occurrence of
tolerance or discontinuation-induced refractoriness may be an ar-
tifact of poor evaluation of the prior course of illness and the de-
gree of treatment responsiveness [17]. Thus, it would appear use-
ful to develop some consensus guidelines about the general rules
of thumb that would characterize and differentiate these phenom-
ena. Since the rate of loss of effectiveness in a tolerance-like pro-
cess differs greatly as a function of the baseline pretreatment ra-
pidity of recurrence of episodes, a single absolute temporal rule
does not sufﬁce.
Rather, we suggest the utility of making the assessments of
long-term efﬁcacy based on the achievement of a response and
well-interval that is much longer than the previously observed
baseline pretreatment well-intervals. One could adopt a crite-
rion that a bonaﬁde response should show a well-interval of at
least two or three times the duration of the previous or average
Figure 6 After several years of ultrarapid cycling of extremely severe BPII
depressionsdespitelithiumtreatment,thepatienthadapartialresponseto
the addition of carbamazepine for about 6 months (1986-1987). However,
severe depressions reemerged, as did manias of increasing severity in a
patternsuggestiveoftolerance.Twobriefperiodsofreresponse(RR)tocar-
bamazepine occurred after several months off drug and the reemergence
ofnewepisodesofdepressionofseveralmonths’durationwhilemedication
free.
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well-intervals [56]. In the recurrent affective disorders, once
breakthrough episodes begin to occur, they may rapidly emerge
with greater severity, frequency, or duration, such that the orig-
inal patterns of illness progression of episodes (seen prior to any
treatment or during inadequate treatment) are replicated or they
may reemerge in an even more accelerated fashion. However, in
other instances, the rate of breakthrough of episodes reﬂecting tol-
erance may proceed extremely slowly, over the course of months
to years, and this makes the prospective charting of mood episodes
of particular importance in the assessment of both initial degree of
effectiveness of a treatment regimen (i.e., the duration of time im-
proved or well) and whether such effectiveness begins to wane
despite continued treatment via a tolerance process.
The rate of tolerance development can be assessed using the
slope of a line drawn at the beginning of the ﬁrst breakthrough
episode to that occurring when full-blown episodes (of a severity
to that previously observed) have emerged (Figure 6). The slope of
this intersecting line, in the context of the prior rapidity of cycling,
might then reﬂect the relative proneness to tolerance development
of that individual. Such an intersecting tangential line could be
drawn for the rate (slope) of breakthrough manic episodes and de-
pressive episodes separately, as each phase may develop tolerance
with different time frames. Such a differential rate would depend
on the relative manic versus depressive illness drive in conjunc-
tion with the relative antimanic versus antimanic effectiveness of
the treatment (Figure 6). Hopefully, with increasing recognition
of different patterns of acquired loss of efﬁcacy– tolerance versus
discontinuation-related refractories– occurring in the course of the
recurrent affective disorders, a more systematic literature about
ways of preventing or slowing tolerance development will become
possible, as well as assessment of the best therapeutic approaches
to its reversal once it has occurred.
It is obviously a tenuous proposition to make inferences about
clinical tolerance development in mood-disordered patients whose
affective episodes and well-intervals may last weeks to months or
even years compared with rodents, whose kindled seizures last
about 60 seconds and duration of treatment response with stimu-
lation given every 24 h is on the order of days to weeks. The study
of the tolerance process and its avoidance and treatment would ad-
vance more rapidly if more adequate animal models of manic and
depressive episodes were available where there were homologous
behaviors and time frames as well as analogous drug effectiveness
to that seen clinically.
Given these acknowledged shortcomings of the preclinical
model of anticonvulsant tolerance development on amygdala-
kindled seizures, we nonetheless hope that some of the princi-
ples observed from its study and the clinical and research ques-
tions it helps formulate will be valuable. The model helps focus
attention on the detailed evaluation of the longitudinal course of
the recurrent mood disorders and on the need for early and sus-
tained prophylactic treatment intervention [44,45,50]. Examining
this preclinical tolerance model may thus be a useful ﬁrst step in
beginning to approach the description and therapeutics of toler-
ance development in the affective disorders.
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